{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T17:45:05Z","timestamp":1744652705625},"reference-count":40,"publisher":"American Institute of Mathematical Sciences (AIMS)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011]]},"DOI":"10.3934\/mbe.2011.8.279","type":"journal-article","created":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T17:58:52Z","timestamp":1303840732000},"page":"279-287","source":"Crossref","is-referenced-by-count":1,"title":["Questions from the fourth son: A clinician reflects on immunomonitoring, surrogate markers and systems biology"],"prefix":"10.3934","volume":"8","member":"2321","reference":[{"key":"1","first-page":"2572","article-title":"<em>Induction of cell mediated immunity to autologous melanomic cells and regression of metatases<\/em>,","volume":"46","author":"D. Berd","year":"1986","journal-title":"Cancer Research"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2007.09.017","article-title":"<em>Gene expression profiling distinguishes a molecular signature for grade 1B mild acute cellular rejection in cardiac allograft recipients<\/em>,","volume":"26","author":"D. Bernstein","year":"2007","journal-title":"The Journal of Heart and Lung Transplantation"},{"key":"3","first-page":"2068","article-title":"<em>Cellular emmunity to autologous breast cancer and R111-murine mammary tumor virus preparations<\/em>,","volume":"38","author":"M. M. Black","year":"1978","journal-title":"Cancer Research"},{"key":"4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0090-4295(99)80301-X","article-title":"<em>Loss of HLA class 1 expression in prostrate cancer: implications for immunotherapy<\/em>,","volume":"46","author":"R. A. Blades","year":"1995","journal-title":"Urology"},{"key":"5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0b013e3181837276","article-title":"<em>Suppressive influences in the immune response to cancer<\/em>,","volume":"32","author":"V. Bronte","year":"2009","journal-title":"Journal of Immunotherapy"},{"key":"6","article-title":"<em>A systematic approach to biomarker discovery<\/em>,","volume":"6","author":"L. H. Butterfield","year":"2008","journal-title":"preamble to"},{"key":"7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jtbi.2003.12.011","article-title":"<em>A stochastic model of cytotoxic T cell responses<\/em>,","volume":"228","author":"D. L. Chao","year":"2004","journal-title":"Journal of Theoretical Biology"},{"key":"8","first-page":"289","article-title":"<em>The development of therapeutic vaccines for the management of malignant melanoma<\/em>,","volume":"26","author":"A. G. Dalgleish","year":"1996","journal-title":"Cancer Survey"},{"key":"9","doi-asserted-by":"crossref","first-page":"7950","DOI":"10.1158\/0008-5472.CAN-05-0564","article-title":"<em>A validated mathematical model of cell-mediated immune response to tumor growth<\/em>,","volume":"65","author":"L. G. de Pillis","year":"2005","journal-title":"Cancer Research"},{"key":"10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/35093109","article-title":"<em>Rae1 and H60 ligands of the NKG2D receptor stimulate tumor immunity<\/em>,","volume":"413","author":"A. Diefenbach","year":"2001","journal-title":"Nature"},{"key":"11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1023\/B:JOCI.0000040928.67495.52","article-title":"<em>Humoral epitope-spreading following immunization with a HER-2\/neu peptide based vaccine in cancer patients<\/em>,","volume":"24","author":"M. L. Disis","year":"2004","journal-title":"Journal of Clinical Immunology"},{"key":"12","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"<em>Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes<\/em>,","volume":"298","author":"M. E. Dudley","year":"2002","journal-title":"Science"},{"key":"13","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood.V88.4.1501.bloodjournal8841501","article-title":"<em>Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer<\/em>,","volume":"88","author":"B. Eibl","year":"1996","journal-title":"Blood"},{"key":"14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3233\/BD-2007-26110","article-title":"<em>Prospects of controlling breast cancer metastasis by immune intervention<\/em>,","volume":"26","author":"A. M. F. Fulton","year":"2006","journal-title":"Breast disease"},{"key":"15","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"<em>Type, density, and location of immune cells within human colorectal tumors predict clinical outcome<\/em>,","volume":"313","author":"J. Galon","year":"2006","journal-title":"Science"},{"key":"16","doi-asserted-by":"publisher","first-page":"7753","DOI":"10.1073\/pnas.0602382103","article-title":"<em>Transferable anticancer innate immunity in spontaneous regression\/complete resistance mice<\/em>,","volume":"103","author":"A. M. Hicks","year":"2006","journal-title":"PNAS"},{"key":"17","doi-asserted-by":"publisher","first-page":"7788","DOI":"10.1158\/0008-5472.CAN-10-1736","article-title":"<em>Selective depletion of <\/em>Foxp3$^+$ <em>regulatory T cells improves effective therapeutic vaccination against established melanoma<\/em>,","volume":"70","author":"K. Klages","year":"2010","journal-title":"Cancer Research"},{"key":"18","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.4049\/jimmunol.163.11.6292","article-title":"<em>Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility in in-vitro stimulation but does not lead to tumor regression<\/em>,","volume":"163","author":"K. -H. Lee","year":"1999","journal-title":"J. Immunol."},{"key":"19","first-page":"1676","article-title":"<em>Complete pathological remission is possible with septemic combination chemotherapy for inoperable hepatocellular carcinoma<\/em>,","volume":"5","author":"T. W. T. Leung","year":"1999","journal-title":"Clinical Cancer Research"},{"key":"20","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1200\/JCO.2009.22.3701","article-title":"<em>Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges<\/em>,","volume":"27","author":"K. S. S. D. Mandrekar","year":"2009","journal-title":"JCO"},{"key":"21","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00002371-199607000-00003","article-title":"<em>Differential anti-MART-1\/MelanA CTL activity in peripheral blook of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in-vivo priming by tumor cells<\/em>,","volume":"19","author":"F. M. Marincola","year":"1996","journal-title":"J. Immunother. Emphasis Tumor Immunol"},{"key":"22","first-page":"7","article-title":"\"Mathematical Methods in Systems Biology,\"","year":"2010","journal-title":"Tel Aviv University"},{"key":"23","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/35082583","article-title":"<em>Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction<\/em> [Erratum appears in Nature 2001 Sep 13;413(6852):183],","volume":"411","author":"A. F. Ochsenbein","year":"2001","journal-title":"Nature"},{"key":"24","article-title":"\"Models of the Innate Immune System: Theory and Medical Implications,''","author":"V. Rom-Kedar","year":"2010","journal-title":"Presentation"},{"key":"25","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.4049\/jimmunol.175.9.6169","article-title":"<em>Tumor progression can occur despite the induction of very high levelsof Self\/Tumor antigen-specific CD8+ t cells in Patiens w Melanoma<\/em>,","volume":"175","author":"S. Rosenberg","year":"2005","journal-title":"J immunol"},{"key":"26","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1158\/1078-0432.CCR-07-0588","article-title":"<em>Cancer vaccines: Moving beyond current paradigms<\/em>,","volume":"13","author":"J. Schlom","year":"2007","journal-title":"Clinical Cancer Research"},{"key":"27","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3181\/0708-MR-226","article-title":"<em>Paradigm shifts in cancer vaccine therapy<\/em>,","volume":"233","author":"J. Schlom","year":"2008","journal-title":"Experimental Biology and Medicine"},{"key":"28","article-title":"\"Smoking and Health,''","year":"1103","journal-title":"Report of the Advisory Committee to the Surgeon General of the Public Health Service"},{"key":"29","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/oxfordjournals.aje.a115939","article-title":"<em>What is a cause and how do we know one? A grammar for pragmatic epidemiology<\/em>,","volume":"133","author":"M. Susser","year":"1991","journal-title":"Am. J. of Epidemiology"},{"key":"30","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/bioinformatics\/bti239","article-title":"<em>Quantifying the relevance of different mediators in the human immune cell network<\/em>,","volume":"21","author":"P. Tieri","year":"2005","journal-title":"Bioinformatics"},{"key":"31","first-page":"297","article-title":"<em>Antitumor vaccines, immunotherapy and the immunological constant of rejection<\/em>,","volume":"12","author":"E. Wang","year":"2009","journal-title":"Idrugs"},{"key":"32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.it.2008.03.002","article-title":"<em>The immunologic constant of rejection<\/em>,","volume":"29","author":"E. Wang","year":"2008","journal-title":"Trends in Immunology"},{"key":"33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2174\/156800907782418310","article-title":"<em>Anti-tumor vaccines in head and neck cancer: Targeting immune responses to the tumor<\/em>,","volume":"7","author":"T. L. Whiteside","year":"2007","journal-title":"Current Cancer Drug Targets"},{"key":"34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/BF02618388","article-title":"<em>Autologous and homologous immunofluorescent antibody to established breast cancer cell lines<\/em>,","volume":"16","author":"C. Wiseman","year":"1980","journal-title":"In Vitro"},{"key":"35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1749-6632.1993.tb44040.x","article-title":"<em>Clinical responses to intralymphatic whole-cell melanoma vaccine augmented by in vitro incubation with alpha-interferon<\/em>,","volume":"690","author":"C. Wiseman","year":"1993","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"36","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1075-122X.2006.00319.x","article-title":"<em>Objective clinical regression of metastatic breast cancer in disparate sites after use of whole-cell vaccine genetically modified to release sargramostim<\/em>,","volume":"12","author":"C. L. Wiseman","year":"2006","journal-title":"Breast Journal"},{"key":"37","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.2003.12.065","article-title":"<em>How can we tell when cancer vaccines vaccinate<\/em>,","volume":"21","author":"J. D. Wolchok","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"38","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"<em>Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria<\/em>,","volume":"15","author":"J. D. Wolchok","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"39","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1158\/0008-5472.CAN-07-6822","article-title":"<em>Signatures associated with rejection or recurrence in HER-2\/neu-positive mammary tumors<\/em>,","volume":"68","author":"A. Worschech","year":"2008","journal-title":"Cancer Res."},{"key":"40","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/CJI.0b013e318197b1b2","article-title":"<em>Application of a flow cytometric cytotoxicity assay for monitoring cancer vaccine trials<\/em>,","volume":"32","author":"L. Zaritskaya","year":"2009","journal-title":"Journal of Immunotherapy"}],"container-title":["Mathematical Biosciences and Engineering"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.aimspress.com\/article\/10.3934\/mbe.2011.8.279\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T11:06:56Z","timestamp":1712401616000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.aimspress.com\/article\/10.3934\/mbe.2011.8.279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.3934\/mbe.2011.8.279","relation":{},"ISSN":["1551-0018"],"issn-type":[{"value":"1551-0018","type":"print"}],"subject":[],"published":{"date-parts":[[2011]]}}}